B. Riley raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $24 from $20 and keeps a Neutral rating on the shares following the Q4 report. The upside was driven primarily by stronger than expected net product sales and an uptick in contract revenues from collaborations, the analyst tells investors in a research note. The firm increased estimates following the earnings report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel’s Promising Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- Rigel Pharmaceuticals Reports Strong 2024 Financial Results
- Rigel Pharmaceuticals reports Q4 EPS 80c, consensus 58c
- Rigel Pharmaceuticals sees FY25 revenue $200M-$210M, consensus $204.88M
- RIGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Questions or Comments about the article? Write to editor@tipranks.com